Cost-effectiveness of stereotactic body radiotherapy in the treatment of non-small-cell lung cancer (NSCLC): a systematic review

被引:5
|
作者
Sun, Hui [1 ,2 ,3 ]
Jin, Chunlin [3 ]
Wang, Huishan [4 ]
Hu, Shanlian [1 ]
Chen, Yingyao [1 ,2 ]
Wang, Haiyin [3 ]
机构
[1] Fudan Univ, Sch Publ Hlth, Shanghai 200032, Peoples R China
[2] Fudan Univ, Sch Publ Hlth, Natl Hlth Commiss, Key Lab Hlth Technol Assessment, Shanghai, Peoples R China
[3] Shanghai Med Informat Ctr, Shanghai Hlth Dev Res Ctr, Shanghai, Peoples R China
[4] Shanghai Songjiang Dist Cent Hosp, Dept Gastroenterol, Shanghai, Peoples R China
关键词
Non-small cell lung cancer; stereotactic ablative body radiotherapy; cost-effectiveness; systematic review; RADIATION-THERAPY; ABLATIVE RADIOTHERAPY; PROSTATE-CANCER; SURGERY; RESECTION; SURVIVAL; IMPACT;
D O I
10.1080/14737167.2022.2050217
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives This study aims to systematically review the studies on the cost-effectiveness of stereotactic body radiotherapy (SBRT) in the treatment of non-small-cell lung cancer (NSCLC). Methods A systematic literature search was performed in databases from 2000 through April 2021. The search terms included 'economics,' 'cost,' 'cost effectiveness,' 'SBRT,' and all names for NSCLC. Two reviewers independently screened the titles, abstracts and full texts to determine the studies for the final sample. The quality of the included studies was assessed using the Quality of Health Economic Studies checklist. Results Eleven studies were identified and included in our final review. SBRT was reported to be a cost-effective (5 of 5) option compared to conventional radiotherapy, radiofrequency ablation, and best supportive care for medically inoperable, early-stage NSCLC. However, the identified studies revealed that no single treatment was found to be more cost-effective than others between SBRT and surgical interventions. The key drivers of this cost-effectiveness were the cost of the treatment, utility value, and the rate of surgical mortality. Conclusions SBRT may be considered a more cost-effective strategy for medically inoperable, early-stage NSCLC. Considering the limited studies available, more related research should be conducted to further validate these results.
引用
收藏
页码:723 / 734
页数:12
相关论文
共 50 条
  • [1] Cost-effectiveness of carbon-ion radiotherapy versus stereotactic body radiotherapy for non-small-cell lung cancer
    Okazaki, Shohei
    Shibuya, Kei
    Takura, Tomoyuki
    Miyasaka, Yuhei
    Kawamura, Hidemasa
    Ohno, Tatsuya
    [J]. CANCER SCIENCE, 2022, 113 (02) : 674 - 683
  • [2] Cost-Effectiveness of Pembrolizumab for the treatment of Non-Small-Cell lung cancer: A systematic review
    Zhang, Chuan
    Zhang, Jiaxu
    Tan, Jing
    Tian, Panwen
    Li, Weimin
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] COST-EFFECTIVENESS OF TREATMENT WITH NEW AGENTS IN ADVANCED NON-SMALL-CELL LUNG CANCER: A SYSTEMATIC REVIEW
    Bongers, M. L.
    Coupe, V. M.
    Jansma, E. P.
    Smit, E. F.
    Uyl-de Groot, C.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A451 - A451
  • [4] COST-EFFECTIVENESS OF TREATMENT WITH NEW AGENTS IN ADVANCED NON-SMALL-CELL LUNG CANCER: A SYSTEMATIC REVIEW
    Bongers, Mathilda L.
    Coupe, Veerle M. H.
    Jansma, E. P.
    Smit, Egbert F.
    Uyl-de Groot, Carin A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1225 - S1226
  • [5] Cost-Effectiveness Analysis Comparing Conventional Versus Stereotactic Body Radiotherapy for Surgically Ineligible Stage I Non-Small-Cell Lung Cancer
    Mitera, Gunita
    Swaminath, Anand
    Rudoler, David
    Seereeram, Colleen
    Giuliani, Meredith
    Leighl, Natasha
    Gutierrez, Eric
    Dobrow, Mark J.
    Coyte, Peter C.
    Yung, Terence
    Bezjak, Andrea
    Hope, Andrew J.
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2014, 10 (03) : E130 - E136
  • [6] Cost-effectiveness of chemotherapy in non-small-cell lung cancer
    Saglam, S
    Yetis, B
    Ozyilkan, O
    Akçali, Z
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3750 - 3751
  • [7] A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
    Lange, Ansgar
    Prenzler, Anne
    Frank, Martin
    Golpon, Heiko
    Welte, Tobias
    von der Schulenburg, J-Matthias
    [J]. BMC PULMONARY MEDICINE, 2014, 14
  • [8] A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
    Ansgar Lange
    Anne Prenzler
    Martin Frank
    Heiko Golpon
    Tobias Welte
    J-Matthias von der Schulenburg
    [J]. BMC Pulmonary Medicine, 14
  • [9] PROGNOSTIC FACTORS IN STEREOTACTIC BODY RADIOTHERAPY FOR NON-SMALL-CELL LUNG CANCER
    Matsuo, Yukinori
    Shibuya, Keiko
    Nagata, Yasushi
    Takayama, Kenji
    Norihisa, Yoshiki
    Mizowaki, Takashi
    Narabayashi, Masaru
    Sakanaka, Katsuyuki
    Hiraoka, Masahiro
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (04): : 1104 - 1111
  • [10] Cost Effectiveness of Treatment With New Agents in Advanced Non-Small-Cell Lung Cancer A Systematic Review
    Bongers, Mathilda L.
    Coupe, Veerle M. H.
    Jansma, Elise P.
    Smit, Egbert F.
    Uyl-de Groot, Carin A.
    [J]. PHARMACOECONOMICS, 2012, 30 (01) : 17 - 34